Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Cash from Investing Activities (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Cash from Investing Activities data on record, last reported at $28.3 million in Q3 2025.

  • For Q3 2025, Cash from Investing Activities fell 41.3% year-over-year to $28.3 million; the TTM value through Sep 2025 reached $131.5 million, up 28.6%, while the annual FY2024 figure was $176.6 million, 497.14% up from the prior year.
  • Cash from Investing Activities reached $28.3 million in Q3 2025 per ZNTL's latest filing, down from $30.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $72.9 million in Q2 2023 and bottomed at -$142.1 million in Q2 2022.
  • Average Cash from Investing Activities over 4 years is $7.8 million, with a median of $30.4 million recorded in 2025.
  • Peak YoY movement for Cash from Investing Activities: plummeted 686.73% in 2023, then skyrocketed 176.75% in 2024.
  • A 4-year view of Cash from Investing Activities shows it stood at -$11.9 million in 2022, then crashed by 253.62% to -$42.1 million in 2023, then skyrocketed by 176.75% to $32.3 million in 2024, then decreased by 12.27% to $28.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $28.3 million in Q3 2025, $30.4 million in Q2 2025, and $40.5 million in Q1 2025.